Percutaneous Systems (PercSys), a developer and marketer of the PercSys Accordion family of kidney and ureteral stone devices, has appointed Gary Curtis as president and CEO.
Curtis has recently served as CEO of Concentric Medical, and prior to that he served as president and CEO of RadioTherapeutics, until its acquisition by Boston Scientific in 2001.
Prior to RadioTherapeutics, Curtis served as executive vice president of Sales and Marketing, at Fusion Medical, general manager of the Peripheral Systems Division at Advanced Cardiovascular Systems (ACS), and prior to that, as VP of Sales at ACS.
PercSys founder and prior CEO Robert Behl said that Gary brings a wealth of medical device management experience to PercSys.
"There is no better person in the industry to drive our sales growth and continuing innovation and we had an absolutely terrific and successful working partnership when we served together previously at RadioTherapeutics, and we look forward to more of the same," Behl said.
Curtis said that PercSys is approaching the final stages of the development of the ‘game changing’ MicroStent device for patients experiencing the disabling pain of kidney stones and he was excited about working with the PercSys team in continued market development for the current Accordion family of stone products, while simultaneously refining and preparing to launch the MicroStent device.